AZD5582

InvivoChem Cat #:V4256CAS #:1258392-53-8 Purity >=98%

Description: AZD5582 is a novel and potent IAP (Inhibitor of apoptosis proteins) antagonist which binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP with IC50s of 15, 21, and 15 nM, respectively. AZD5582 causes cIAP1 degradation and induces apoptosis in the MDA-MB-231 breast cancer cell line at subnanomolar concentrations in vitro. When administered intravenously to MDA-MB-231 xenograft-bearing mice, AZD5582 results in cIAP1 degradation and caspase-3 cleavage within tumor cells and causes substantial tumor regressions following two weekly doses of 3.0 mg/kg. Antiproliferative effects are observed with AZD5582 in only a small subset of the over 200 cancer cell lines examined, consistent with other published IAP inhibitors. As a result of its in vitro and in vivo profile, AZD5582 was nominated as a candidate for clinical development.

Description:

References: J Med Chem. 2013 Dec 27; 56(24):9897-919.; Pharmacol Res Perspect. 2014 Dec; 2(6):e00081.

References:

-20C for 3 years in powder form

Synonym: AZD5582; AZD-5582; AZD 5582.
IUPAC/Chemical Name: (S, S, 2S, 2?S)-N, N?-((1S, 1?S, 2R, 2?R)-2, 2?-(Hexa-2, 4-diyne-1, 6-diylbis(oxy))bis(2, 3-dihydro-1H-indene-2, 1-diyl))bis(1-((S)-2-cyclohexyl-2-((S)-2-(methylamino)propanamido)acetyl)-pyrrolidine-2-carboxamide).
InChi Key: WLMCRYCCYXHPQF-ZVMUOSSASA-N
InChi Code: InChI=1S/C58H78N8O8/c1-37(59-3)53(67)61-49(39-21-9-7-10-22-39)57(71)65-31-19-29-45(65)55(69)63-51-43-27-15-13-25-41(43)35-47(51)73-33-17-5-6-18-34-74-48-36-42-26-14-16-28-44(42)52(48)64-56(70)46-30-20-32-66(46)58(72)50(40-23-11-8-12-24-40)62-54(68)38(2)60-4/h13-16, 25-28, 37-40, 45-52, 59-60H, 7-12, 19-24, 29-36H2, 1-4H3, (H, 61, 67)(H, 62, 68)(H, 63, 69)(H, 64, 70)/t37-, 38-, 45-, 46-, 47+, 48+, 49-, 50-, 51-, 52-/m0/s1
SMILES Code: CN[CH](C)C(N[CH](C1CCCCC1)C(N2[CH](C(N[CH]3C(C=CC=C4)=C4C[CH]3OCC#CC#CCO[CH]5CC6=C(C=CC=C6)[CH]5NC([CH](CCC7)N7C([CH](C8CCCCC8)NC([CH](C)NC)=O)=O)=O)=O)CCC2)=O)=O.